Selvita Oncology is a biopharmaceutical company that specializes in the discovery and development of novel cancer therapies. The company is based in Poland and focuses on the discovery and development of new drugs to treat a wide range of cancer types. Selvita Oncology aims to develop new therapies that target specific genetic mutations and pathways that are involved in cancer growth, with the goal of improving treatment outcomes for patients.
One of the key areas of focus for Selvita Oncology is the development of small molecule kinase inhibitors. Kinases are enzymes that play a key role in cancer growth and progression, and inhibiting their activity can help to slow or stop the growth of cancer cells. Selvita Oncology is developing a pipeline of small molecule kinase inhibitors that target specific genetic mutations and pathways that are involved in cancer growth.
In addition to its small molecule kinase inhibitors, Selvita Oncology is also working on the development of new cancer immunotherapies. Immunotherapies are a new class of cancer treatments that work by stimulating the body's own immune system to fight cancer. Selvita Oncology is developing new immunotherapies that target specific genetic mutations and pathways that are involved in cancer growth, with the goal of improving treatment outcomes for patients.
Selvita Oncology is also heavily involved in collaborations and partnerships with other biopharmaceutical companies and research institutions in order to expand its reach and capabilities. The company has multiple ongoing collaborations with other pharmaceutical companies, academic and research institutions, as well as biotech companies.
One of Selvita Oncology's most promising drugs in development is SEL24/MEN1703, an oral, pan-fibroblast growth factor receptor (FGFR) inhibitor that is in Phase 1 clinical trial for the treatment of solid tumors. SEL24/MEN1703 targets the FGFR family of kinases, which play a key role in cancer growth and progression.
Another promising drug in development is SEL120/MEN1309, a first-in-class, oral, selective and potent inhibitor of the protein kinase DDR1, that is in phase 1 clinical trials for the treatment of solid tumors, which is the first drug targeting DDR1 protein kinase that is in clinical development. DDR1 is a protein kinase that is involved in cancer growth and progression.
Overall, Selvita Oncology is a biopharmaceutical company that is focused on the discovery and development of novel cancer therapies. The company is developing a pipeline of small molecule kinase inhibitors and cancer immunotherapies that target specific genetic mutations and pathways that are involved in cancer growth, with the goal of improving treatment outcomes for patients. Selvita Oncology's focus on collaborations and partnerships allows for the ability to expand its reach and capabilities in the field of oncology.
No comments:
Post a Comment